|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Departments of Neurology, Pediatrics, and
Radiology and the Center for Health Care Research, Medical University
of South Carolina, Charleston, SC; and the Department of Pediatrics,
Medical College of Virginia, Richmond, VA.
We conducted a retrospective study to determine whether the
presence of moyamoya collaterals influenced the risk of recurrence of
cerebrovascular events (CVEs: stroke or transient ischemic attack) in
patients with sickle cell disease placed on chronic transfusions after
a stroke. Forty-three patients with homozygous sickle cell anemia
(HbSS) and 1 with HbSOArab (16 females, 28 males) who had
suffered strokes while under the age of 18 were studied. All patients
had been on transfusions aimed at maintaining the sickle hemoglobin
(HbS) level below 30%. They were followed for a mean of 6.6 years (2.2 to 20.4 years). The presence of collaterals was diagnosed based on
either magnetic resonance angiography or conventional angiography.
Eighteen (41%) of the 44 patients suffered recurrent CVEs. Nineteen
(43%) (6 females, 13 males) patients had moyamoya collaterals. Eleven
(58%) of these 19 experienced 21 total recurrent CVEs, including 4 strokes in 4 patients (21%). In comparison, 7 (28%) of 25 patients
without moyamoya collaterals experienced 9 recurrent CVEs
(P < .05) with only 1 recurrent stroke (4%). Moyamoya
patients were also more likely to have 2 recurrent CVEs (42% vs 8%,
P < .05) as well as poorer neuropsychological testing
results. A proportional hazards regression analysis indicated that
patients with moyamoya were more than twice as likely to incur a
subsequent CVE (hazard ratio, 2.40; 95% confidence interval, 0.85, 6.75). We conclude that up to 41% of patients with sickle cell disease
experience recurrent CVEs after an initial stroke despite chronic
transfusions and that the risk of recurrence is significantly higher
for those who have moyamoya collaterals.
(Blood. 2002;99:3144-3150) Ischemic stroke develops in 7% to 11% of children
with homozygous sickle cell anemia (HbSS).1-5 In most
cases strokes are the result of large-vessel occlusive disease and
watershed ischemia confirmed by cerebral angiography.6-8
Moyamoya (Japanese for "hazy puff of smoke") disease describes an
angiographic pattern consisting of large-vessel occlusion and a
telangiectatic network of collateral vessels of unknown etiology
usually seen in children who present with acute
hemiplegia.9,10 This is the result of progressive
development of collaterals after occlusion of large cerebral vessels.
Moyamoya syndrome or pattern refers to the same angiographic changes
when they are the result of diseases such as neurofibromatosis,
tuberous sclerosis, sickle cell, periarteritis nodosa, postradiation
vasculopathy, or infections.11 Conventional angiograms
performed after a stroke in children with sickle cell anemia were first
reported in 1972 to have a moyamoya pattern.8
After a stroke, an estimated 44% to 67% of HbSS patients experience
recurrent infarctions.2,4,12 Chronic transfusion therapy
programs that have the goal of maintaining sickle hemoglobin (HbS)
levels below 30% can reduce the risk of recurrent stroke to 13% but
seem to have little effect on the recurrence of other transient
neurologic events or hemorrhagic strokes.13 Transfusions seem to be needed long-term because up to 50% of patients on
transfusion have a recurrent stroke after transfusions are
discontinued.14 Nonetheless, strokes can recur despite
chronic transfusion,15 although it has been reported that
maintaining HbS levels below 10% can prevent most
recurrences.3 Moyamoya syndrome has been recently shown to
be a predictor of recurrent stroke after cerebral arterial infarction
in non-sickle cell patients.16 It is unclear if moyamoya
pattern in sickle cell anemia is associated with an increased risk of
recurrent stroke or transient ischemic attack (TIA). To investigate
this issue, we retrospectively collected data to evaluate the
recurrence risk of stroke or TIA in children with HbSS who were on a
transfusion therapy program after having an initial acute clinical stroke.
We reviewed the records of all patients with sickle cell anemia
in our institution who had an acute stroke when they were less than 18 years of age between January 1980 and August 1999. All were enrolled in
the chronic transfusion program. Patients received transfusions every 3 to 5 weeks aimed at maintaining the level of HbS below 30% and were
followed for a minimum of 1 year after occurrence of initial stroke.
This study was deemed to be exempt from the need for informed consent
by the Institutional Review Board at the Medical University of
South Carolina.
For the purpose of this study, we defined a cerebrovascular event (CVE)
to include a stroke or TIA, with each considered a different-type
event. Infarctive and hemorrhagic strokes were defined as neurologic
events lasting more than 24 hours associated with or without
radiographic evidence of new areas of infarction or hemorrhage,
respectively. TIA was defined as focal neurologic symptoms such as
weakness or hypoesthesia of fewer than 24 hours' duration and without
radiographic changes.5,13
Data collected from charts and radiologic reviews on all patients
included baseline complete blood counts, including levels of HbS and
fetal hemoglobin, age at initial acute stroke, and associated clinical
and radiographic manifestations. Similar data were recorded for any
subsequent CVE during their follow-up evaluations. Most patients
diagnosed before 1991 had computed tomography scans after their stroke,
and magnetic resonance imaging/magnetic resonance angiography (MRI/MRA)
was performed as part of their follow-up. After 1994 we followed a
uniform protocol for evaluating strokes and TIA. All patients had
MRI/MRA as soon as possible after the initial event and each subsequent
event. They also had documented neurology consultations after each
event. Neurology consultation and imaging studies were repeated yearly.
Before MRA was available, cerebral angiograms were performed on
patients who experienced recurrent events. All imaging studies were
reviewed by one neuroradiologist (J.K.C.).
MRI examinations were performed on a 1.5 T superconducting magnet
(Sigma, General Electric Medical Systems, Milwaukee, WI). MRA
examinations consisted of axially acquired 3-dimensional Fourier transformation (3DFT) time of flight studies of the cerebral
vessels, supplemented in some cases by 2DFT and 3DFT phase contrast
MRAs. Several early patients underwent conventional angiography
consisting of cut-film anteroposterior and lateral views supplemented
by digital subtraction angiography for analysis of subtle collateral flow patterns. Nonionic contrast (Omnipaque 300, Winthrop
Pharmaceuticals, New York, NY) was used in all cases.
Patients' HbS levels were maintained at 25% or less, and patients
were well hydrated before and during the procedure. Normal oxygen
saturation was maintained throughout the procedure and was monitored by
pulse oximetry.
MRI studies were reviewed to assess the presence and locations of
cerebral infarcts. MRAs and conventional angiograms were reviewed to
identify the moyamoya pattern. Moyamoya findings were defined by
vascular stenosis and occlusion of the supraclinoid portions of the
internal carotid arteries or the proximal parts of the anterior and
middle cerebral arteries, accompanied by patterns of collateral blood
flow through the basal ganglia and/or meningeal anastomoses.17,18
Patients with moyamoya collaterals were compared with patients without
moyamoya on the following measures: gender, current age, age at first
stroke, length of follow-up, proportion having a subsequent CVE,
proportion having 2 subsequent CVEs, proportion having a subsequent
stroke, proportion having subsequent TIA, and baseline laboratory
values. Preliminary results from neuropsychological functioning tests
have been previously reported on patients from these 2 groups.19
Using nonparametric log-rank statistics, the time to subsequent CVE was
compared between moyamoya patients and nonmoyamoya patients.
Kaplan-Meier techniques were used to calculate the median time to
subsequent CVE and the median time to subsequent stroke. To estimate
hazard ratios comparing event rates in moyamoya patients with
nonmoyamoya patients, proportional hazards regression models were
created. The primary analysis included all eligible patients and all
CVEs, while secondary analyses excluded data from 3 CVEs incurred by 3 patients (2 moyamoya and 1 nonmoyamoya) who were not being transfused
secondary to noncompliance at the time of the event.
Forty-four patients (16 females and 28 males) were studied who had
initial acute strokes between January 1, 1980, and August 1, 1999; all
but one (HbSOArab) had HbSS. Characteristics of
patients with and without moyamoya are listed
in Table 1.
Presence of moyamoya
Timing of imaging studies Because of the nature of this study, imaging studies were performed at varying times after the initial event as described above. Nonetheless, 12 (63%) of 19 patients with moyamoya and 16 (64%) of 25 patients without moyamoya had MRAs or cerebral angiograms performed within 2 months of the initial event. Six (13%) of the 44 patients did not have any imaging studies performed within 6 months of the initial event and were diagnosed clinically. Infarcts were documented in subsequent studies in all 6 patients. Details of the timing of studies are presented in Tables 2 and 3.Initial stroke The mean age at the time of the first acute clinical stroke was 7.8 years (range, 1.1 to 16.9 years) for moyamoya patients and 7.4 years (range, 1.7 to 13.9 years) for those without moyamoya. The initial stroke for all 44 patients was infarctive in nature. One nonmoyamoya patient had a hemorrhagic parietal infarct and has not had a recurrent event in 13 years of follow-up. Most strokes were in the areas of distribution of the middle cerebral arteries, anterior cerebral arteries, or watershed areas (frontal and/or parietal lobes). Eight (18%) of 44 patients 2 with moyamoyahad evidence of old
infarcts on scan at the time of their initial acute clinical stroke.
Follow-up time after initial stroke At the time of this report, patients with moyamoya have been followed a median of 8.1 years (interquartile range, 5.0 to 11.5 years) after the initial stroke, while nonmoyamoya patients have been followed a median of 4.7 years (interquartile range, 3.6 to 13.4 years). One patient died after 13.5 years of follow-up due to complications of iron overload, and 2 patients moved out of the area after 4 and 11.5 years of follow-up, respectively.Recurrent CVE Eighteen (41%) of 44 of the patients studied experienced recurrent CVEs, including 5 patients with strokes. Of the 19 patients exhibiting moyamoya pattern, 11 (57.9%) experienced 21 total CVE (stroke or TIA) recurrences. Four patients had recurrent strokes, 10 had TIAs, and 3 patients experienced both. Four of the 11 patients experienced 7 recurrent events (2 strokes and 5 TIAs) with contralateral symptoms when compared with the initial event. Seven (28.0%) of 25 patients without moyamoya vessels experienced 9 total recurrent CVEs. One patient had a recurrent stroke (which occurred while off transfusions), and 6 had 1 or 2 TIAs. Two of 7 patients had recurrent events (1 stroke and 1 TIA) with contralateral symptoms compared with the initial event. Thus, patients with moyamoya were significantly more likely to have a recurrent CVE (stroke or TIA) during the period of this study (57.9% vs 28.0%; P < .05). They were also more likely to have 2 subsequent CVEs (42.1% vs 8.0%; P < .05). When recurrent strokes are considered by themselves, the data suggest that moyamoya patients had more subsequent strokes than nonmoyamoya patients (21.1% vs 4.0%, P = .078); however, this parameter did not reach statistical significance. Of the 8 patients with evidence of old infarcts on scan at the time of their initial acute clinical stroke, 1 moyamoya patient had a recurrent stroke, 1 moyamoya patient had a recurrent TIA, and 1 nonmoyamoya patient had a recurrent TIA.Time to subsequent CVE A Kaplan-Meier survival curve was generated to show the difference in time to second CVE between the 2 groups (Figure 1). The median time to recurrent CVE after initial stroke for moyamoya patients was 3.1 years but was not estimable for nonmoyamoya patients because most of those patients did not have a recurrent CVE. The proportional hazards regression analysis indicated that patients with moyamoya were more than 2 times as likely, on average, to incur a subsequent CVE (hazard ratio [HR], 2.40; 95% confidence interval [CI], 0.85-6.75). When CVEs incurred while off transfusion were excluded, the results remained relatively unchanged (HR, 2.41; 95% CI, 0.93-6.22).
Large vessel abnormalities on imaging All moyamoya patients had evidence of severe large vessel disease on every imaging study done, with 16 (84%) of 19 eventually developing complete occlusion and the remaining 3 of 19 having severe stenosis of at least 1 major vessel (Table 2). Two of the 19 patients (nos. 2 and 14) did not have collateral vessels visualized initially, but these were observed in studies performed 1 year or less after the initial event. Thirteen patients with moyamoya were shown to have progressive vessel narrowing on follow-up MRAs. Vessel disease was present but clearly less severe among patients without moyamoya (Table 3), because only 6 (24%) of 25 patients developed complete occlusion of a major vessel. In fact, another 6 (24%) of 25 nonmoyamoya patients had normal MRA findings at initial stroke presentation. One of these 6 (no. 26) experienced 2 recurrent CVEs (TIAs at 3 months and 23 months after initial stroke). This patient's MRAs remained normal through follow-up. Two of the 6 patients (nos. 37 and 40) went on to develop large vessel changes on MRA, with no signs of collateral vessels. Average time of follow-up for these 6 patients is 7.9 years (range, 2.2 to 16.3 years). Progressive large vessel disease was observed more often in moyamoya patients (13 of 19; 68%) when compared with nonmoyamoya patients (11 of 25; 44%). Some of the progressive abnormalities detected may have been due to improved imaging techniques.Hematologic parameters Mean baseline levels of HbS were similar between moyamoya and nonmoyamoya patients (83.0% vs 86.5%) and were not predictive of recurrent events. Other baseline hematologic values, including white count and proportion of fetal hemoglobin, were also not significantly predictive of recurrent neurologic events (Table 1).CVEs off transfusion We treated all patients who had an initial stroke with a program of chronic transfusion every 3 to 5 weeks aimed at keeping HbS below 30%. In the group of patients studied, 3 had recurrent events during a period of noncompliance with transfusion therapy. Two patients with moyamoya suffered recurrent CVEs (1 stroke and 1 TIA) while off transfusion. One of these patients was on hydroxyurea therapy at the time of recurrent TIA with questionable compliance. The only nonmoyamoya patient who had a recurrent stroke was not receiving transfusions at the time. The mean HbS level was 89.8% (range, 86.5% to 91.9%) in these 3 patients at the time of the recurrent CVE. In comparison, the mean HbS was 39.0% (range, 12.1% to 73.0%) at the time of recurrent events in patients on transfusion. When these 3 noncompliant patients were excluded from the analysis and only recurrent CVEs that occurred while patients were on transfusion were considered, the results remained unchanged. All 3 patients have been compliant with chronic transfusion since their recurrent events.Silent stroke In addition to the above patients who presented with an initial acute clinical stroke, the records of 7 HbSS patients who did not present with acute stroke but had MRI/MRA performed for other neurologic symptoms (falloff in school performance, headaches, seizures, syncope, mild memory defect) were reviewed. These 7 patients had no acute MRI changes but did have evidence of old silent infarcts that could have explained some of their presenting symptoms. Three of the patients had moyamoya. These patients have been followed an average of 4.0 years (range, 2.5 to 6.5 years) with no recurrent events. Based on the absence of an initial acute motor stroke presentation, these patients were excluded from statistical analyses in this study. Thus, on initial presentation, 8 (18.2%) of 44 study patients, plus 7 with other neurologic abnormalities in the absence of acute motor presentationa total of 15 (29.4%) of 51had evidence of old infarcts.
Chronic transfusions are effective in preventing the recurrence of infarctive strokes in patients with sickle cell disease (SCD).6,13,21 The reasons why some patients develop recurrences15 while complying with transfusions are unknown. In this regard there are no reports correlating angiographic or MRA findings with the clinical course. In our series of patients with SCD who had suffered an infarctive stroke, a large proportion (41%) had recurrent strokes and/or TIAs despite chronic transfusions. This recurrence rate is higher than previously reported13 and may reflect the careful documentation of neurologic events. In this group of patients the prevalence of moyamoya collaterals was similar to what has been described by others,8 but the male preponderance was different.8,23 Patients with moyamoya collaterals were found to be at higher risk for recurrent strokes and TIAs compared with patients without these collaterals. Cerebral hemorrhages were not observed, perhaps due to the young age of our patients and the relatively short follow-up. The significance of recurrent TIAs has not been well studied in SCD. In other settings it has been argued that a TIA is the mildest end of a spectrum of ischemic cerebrovascular disease that should not be considered as a separate illness from stroke.22 In one large series of patients with SCD, TIAs were found to be highly predictive of a first ischemic stroke.5 In contrast, TIAs were not found to be associated with or predictive of a second (recurrent) stroke in a different series of patients.13 This was also the case among our patients, where only 3 of 16 who experienced recurrent TIAs developed strokes. Patients with moyamoya vessels did worse on neuropsychological evaluations. Neuropsychological tests (Weschler Intelligence Scale, Woodcock-Johnson Psychoeducational Battery, Wide Range Assessment of Memory and Learning, Visual Motor Integration, and others) were performed on a group of 16 patients that included 14 patients reported above. The results revealed significant differences between patients with moyamoya and patients without moyamoya collaterals on verbal IQ, performance IQ, full-scale IQ, math achievement, visual memory, and aphasic symptomatology.19 Subjects with moyamoya collaterals consistently showed greater impairments in both verbal and visual-spatial intellectual abilities and were found to be achieving less well in all areas of psychoeducational abilities. These findings and the increase in recurrent CVEs suggest that moyamoya collaterals are a marker for severe global cerebrovascular disease. Further neuropsychological studies are, however, needed to verify these results. The effects of transfusions on the cerebral vessel abnormalities in patients with SCD are unknown. One report suggested that certain vessel abnormalities could be reversed.21 In our series, 24 of 44 patients had MRA evidence of progressive large vessel disease after several years on a tightly regulated transfusion protocol. Progressive vessel changes were more common among patients with moyamoya. Thus, it seems unlikely that chronic transfusions will reverse the severe vascular damage seen in these patients. Two of our patients developed new moyamoya collaterals while on transfusions. In contrast, another patient had a normal MRA after initial stroke and has continued to show normal MRAs and unchanged MRIs despite 2 recurrent TIAs. It is therefore unclear whether transfusions will prevent the development of collaterals in patients who do not initially have them. It has been reported that bone marrow transplantation can improve the patency of stenotic vessels and reverse the progression of vasculopathy in SCD.24 We have previously reported on a 9-year-old boy who had mild cognitive and memory defects but no stroke. He was found to have extensive moyamoya collaterals and a silent infarct before transplantation for recurrent acute chest syndrome.25 These findings remain unchanged 7 years after successful bone marrow transplantation, suggesting stabilization of vessel disease. In our series, MRA defined the patterns of vascular abnormality and correlated well with conventional angiography when this was performed, as has been shown by others.7,18,26-28 MRI and MRA are relatively easy to perform and carry none of the risks associated with administration of contrast. These tests may provide significant information in SCD patients who have suffered a stroke or have "soft" signs of central nervous system dysfunction as demonstrated in our patients with silent infarcts. Future studies, with techniques such as diffusion and perfusion imaging, transcranial Doppler, and quantitative MRI may help clarify the pathophysiology of strokes and moyamoya formation.29 Our findings suggest that patients with SCD have a high rate of recurrent CVE after initial stroke. Furthermore, transfusions were more effective in preventing TIA and stroke recurrences in patients without severe vessel disease and moyamoya vessels. In a recent report, hydroxyurea and phlebotomy were used for stroke prevention in SCD with promising results.30 However, no radiologic or MRA data about these patients were provided. It may well be that hydroxyurea is more effective in preventing stroke among patients with less severe vessel disease. Noninvasive techniques such as MRA could be used prospectively to help identify patients at risk for recurrent CVE and to study the responses to intervention therapies. Thus, the knowledge of the presence or absence of moyamoya collaterals or other morphologic abnormalities may be important in the design of studies looking at the effects of other agents, such as hydroxyurea, in primary or secondary stroke prevention.
Submitted August 6, 2001; accepted December 18, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Miguel R. Abboud, Dept of Pediatrics, Medical University of South Carolina, 165 Ashley Ave, PO Box 250911, Charleston, SC 29425; e-mail: abboudm{at}musc.edu.
1. Sarnaik SA, Lusher JM. Neurological complications of sickle cell anemia. Pediatr Hematol Oncol. 1982;4:386-394. 2. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65:461-471[CrossRef][Medline] [Order article via Infotrieve]. 3. Moohr JW, Wilson H, Pang EJ-M. Strokes and their management in sickle cell disease. In: Walter FM, ed. Comparative Clinical Aspects of Sickle Cell Disease. New York, NY: Elsevier North Holland; 1982:101-112. 4. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120:360-366[CrossRef][Medline] [Order article via Infotrieve].
5.
Ohene-Frempong K, Weiner SJ, Sleeper LA, et al.
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
Blood.
1998;91:288-294 6. Pavlakis SG, Prohovnik I, Piomelli S, DeVivo DC. Neurologic complications of sickle cell disease. Adv Pediatr. 1989;36:247-276[Medline] [Order article via Infotrieve].
7.
Adams R, Nichols F, McKie V, McKie K, Milner P, Gammal T.
Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI.
Neurology.
1988;38:1012-1017 8. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med. 1972;287:846-849. 9. Maki Y, Enomoto T. Moyamoya disease. Childs Nerv Syst. 1988;4:204-212[CrossRef][Medline] [Order article via Infotrieve].
10.
Suzuki J, Kodama N.
Moyamoya disease 11. Pavlakis SG, Gould RJ, Zito JL. Stroke in children. Adv Pediatr. 1991;38:151-179[Medline] [Order article via Infotrieve]. 12. Sarnaik S, Soorya D, Kim J, Ravindranath Y, Lusher J. Periodic transfusions for sickle cell anemia and CNS infarction. Am J Dis Child. 1979;133:1254-1257[Abstract]. 13. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896-899[CrossRef][Medline] [Order article via Infotrieve]. 14. Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;118:377-382[CrossRef][Medline] [Order article via Infotrieve]. 15. Buchanan GR, Bowman WP, Smith SJ. Recurrent cerebral ischemia during hypertransfusion therapy in sickle cell anemia. J Pediatr. 1983;103:921-923[CrossRef][Medline] [Order article via Infotrieve].
16.
Chabrier S, Husson B, Lasjaunias P, Landrieu P, Tardieu M.
Stroke in childhood: outcome and recurrence risk by mechanism in 59 patients.
J Child Neurol.
2000;15:290-294 17. Demaerel P, Wilms G, Casaer P, et al. Moyamoya disease: MRI and MR angiography. Neuroradiology. 1991;33(suppl):50-52.
18.
Fujisawa I, Asato R, Nishimura K, et al.
Moyamoya disease: MR imaging.
Radiology.
1987;164:103-105 19. Shimoda KC, Waid LR, Abboud MR, et al. Neuropsychological functioning in children with sickle cell disease and stroke. Clin Neuropsychol [abstract]. 1994;8:332a.
20.
Adams RJ, McKie VC, Hsu L, et al.
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.
N Engl J Med.
1998;339:5-11 21. Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984;64:162-169. 22. Adams HP, Hachinski V, Norris JW. Ischemic Cerebrovascular Disease. New York, NY: Oxford University Press; 2001:5-7. 23. Seeler RA, Royal JE, Powe L, Goldbarg HR. Moyamoya in children with sickle cell anemia and cerebrovascular occlusion. J Pediatr. 1978;92:808-810. 24. Steen RG, Helton KJ, Horwitz EM, et al. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol. 2001;49:222-229[CrossRef][Medline] [Order article via Infotrieve]. 25. Abboud MR, Jackson SM, Barredo J, Holden KR, Cure J, Laver J. Neurologic complications following bone marrow transplantation for sickle cell disease. Bone Marrow Transplant. 1996;17:405-407[Medline] [Order article via Infotrieve]. 26. Wiznitzer M, Ruggieri P, Masaryk TJ, Ross JS, Modic MT, Berman B. Diagnosis of cerebrovascular disease in sickle cell anemia by magnetic resonance angiography. J Pediatr. 1990;117:551-555[CrossRef][Medline] [Order article via Infotrieve]. 27. Saeki N, Silva MN, Kubota M, et al. Comparative performance of magnetic resonance angiography and conventional angiography in moyamoya disease. J Clin Neurosci. 2000;7:112-115[CrossRef][Medline] [Order article via Infotrieve]. 28. Kandeel AY, Zimmerman RA, Ohene-Frempong K. Comparison of magnetic resonance angiography and conventional angiography in sickle cell disease: clinical significance and reliability. Neuroradiology. 1996;38:409-416[Medline] [Order article via Infotrieve]. 29. Kirkham FJ, Calamante F, Bynevelt M, et al. Perfusion magnetic resonance abnormalities in patients with sickle cell disease. Ann Neurol. 2001;49:477-485[CrossRef][Medline] [Order article via Infotrieve].
30.
Were RE, Zimmerman SA, Schultz WH.
Hydroxyurea as an alternative to blood transfusion for the prevention of recurrent stroke in children with sickle cell disease.
Blood.
1999;94:3022-3026
© 2002 by The American Society of Hematology.
| ||||||||||
 |
|
 |
|
  P. Monagle, E. Chalmers, A. Chan, G. deVeber, F. Kirkham, P. Massicotte, and A. D. Michelson Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 887S - 968S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Skardoutsou, K. A. Voudris, S. Mastroyianni, E. Vagiakou, G. Magoufis, and P. Koukoutsakis Moya Moya Syndrome in a Child With Pyruvate Kinase Deficiency and Combined Prothrombotic Factors J Child Neurol, April 1, 2007; 22(4): 474 - 478. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Ganesan, M. Prengler, A. Wade, and F. J. Kirkham Clinical and Radiological Recurrence After Childhood Arterial Ischemic Stroke Circulation, November 14, 2006; 114(20): 2170 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Strouse, M. L. Hulbert, M. R. DeBaun, L. C. Jordan, and J. F. Casella Primary Hemorrhagic Stroke in Children With Sickle Cell Disease Is Associated With Recent Transfusion and Use of Corticosteroids Pediatrics, November 1, 2006; 118(5): 1916 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Lee, S. Piomelli, S. Granger, S. T. Miller, S. Harkness, D. J. Brambilla, R. J. Adams, and for the STOP Study Investigators Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results Blood, August 1, 2006; 108(3): 847 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. S. Platt Prevention and Management of Stroke in Sickle Cell Anemia Hematology, January 1, 2006; 2006(1): 54 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Kornblihtt, S. Cocorullo, C. Miranda, P. Lylyk, P. G. Heller, and F. C. Molinas Moyamoya Syndrome in an Adolescent With Essential Thrombocythemia: Successful Intracranial Carotid Stent Placement Stroke, August 1, 2005; 36(8): e71 - e73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jabbour, A. Taher, A. Shamseddine, and S. F. Atweh Moyamoya Syndrome With Intraventricular Hemorrhage in an Adult With Factor V Leiden Mutation Arch Neurol, July 1, 2005; 62(7): 1144 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lottenberg and K. L. Hassell An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease Hematology, January 1, 2005; 2005(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Driscoll, A. Hurlet, L. Styles, V. McKie, B. Files, N. Olivieri, C. Pegelow, B. Berman, R. Drachtman, K. Patel, et al. Stroke risk in siblings with sickle cell anemia Blood, March 15, 2003; 101(6): 2401 - 2404. [Abstract] [Full Text] [PDF]
|
|
| ||||||||
Top
Abstract
Introduction
0.3 to 11.4 years) after the
initial stroke. In 1 patient, who had abnormal transcranial Doppler
findings and was randomized to the observation arm of the Stroke
Prevention Trial in Sickle Cell Disease (STOP), moyamoya collaterals
were observed 3 months before he had a stroke.